Northwest Biotherapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NWBO research report →
Companywww.nwbio.com
Northwest Biotherapeutics, Inc. , a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer.
- CEO
- Linda F. Powers
- IPO
- 2001
- Employees
- 25
- HQ
- Bethesda, MD, US
Price Chart
Valuation
- Market Cap
- $400.91M
- P/E
- -8.94
- P/S
- 267.81
- P/B
- -10.39
- EV/EBITDA
- -7.74
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -44.89%
- Op Margin
- -3574.01%
- Net Margin
- -2953.84%
- ROE
- 62.89%
- ROIC
- -130.30%
Growth & Income
- Revenue
- $1.38M · -0.29%
- Net Income
- $-61,477,000 · 26.62%
- EPS
- $-0.04 · 38.48%
- Op Income
- $-59,914,000
- FCF YoY
- 20.27%
Performance & Tape
- 52W High
- $0.37
- 52W Low
- $0.19
- 50D MA
- $0.21
- 200D MA
- $0.24
- Beta
- -0.74
- Avg Volume
- 3.07M
Get TickerSpark's AI analysis on NWBO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 29, 24 | BOYNTON ALTON L | other | 1,000,000 |
| Aug 9, 24 | BOSCH MARNIX L | other | 3,000,000 |
| Aug 8, 24 | BOYNTON ALTON L | other | 1,000,000 |
| Jul 26, 24 | MALIK NAVID | sell | 657,895 |
| Nov 16, 23 | MALIK NAVID | sell | 125,000 |
| Nov 17, 23 | MALIK NAVID | sell | 150,000 |
| Nov 17, 23 | MALIK NAVID | sell | 295,000 |
| Apr 3, 23 | BOSCH MARNIX L | other | 119,355 |
| Apr 4, 23 | BOYNTON ALTON L | other | 6,794,191 |
| May 26, 22 | BOYNTON ALTON L | other | 4,900,000 |
Our NWBO Coverage
We haven't published any research on NWBO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NWBO Report →